Adma Biologics (ADMA) EBITDA (2011 - 2025)

Adma Biologics has reported EBITDA for 13 years, with the latest figure at $62.8 million in Q4 2025.

• For the quarter ending Q4 2025, EBITDA rose 63.74% year-over-year to $62.8 million; the trailing twelve-month figure through Dec 2025 stood at $191.4 million (up 37.74% YoY), and the FY2025 full-year result was $191.4 million, up 37.75% from the prior year.
• EBITDA for Q4 2025 stood at $62.8 million, up from $51.0 million in the prior quarter.
• The five-year high for EBITDA was $62.8 million in Q4 2025, with the low at -$15.6 million in Q2 2021.
• Historically, EBITDA has averaged $12.7 million across 5 years, with a median of $4.1 million in 2023.
• Annual changes were most pronounced in 2021 — EBITDA slipped 4.61% — and 2024, when it surged 8387.74%.
• Adma Biologics' EBITDA stood at -$13.2 million in 2021, then soared by 54.07% to -$6.1 million in 2022, then surged by 334.93% to $14.2 million in 2023, then jumped by 169.25% to $38.3 million in 2024, then jumped by 63.74% to $62.8 million in 2025.
• The last three EBITDA figures came in at $62.8 million (Q4 2025), $51.0 million (Q3 2025), and $42.8 million (Q2 2025), per Business Quant data.